If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
121
results.
Updated on
24/12/2025 [07:41:00]
Results 50 to 75 of 121
Absstract of: US2025385912A1
Improved methods and reactants for the chemical synthesis of therapeutic nanoparticles are provided. The nanoparticles comprise a polymeric core, to which is attached one or more homing molecules and one or more therapeutic agents. Improvements in speed, yield and purity are attained using the methods disclosed herein.
Absstract of: US2024156905A1
Fas-associated factor 1 (FAF1) protein-loaded exosomes and a cancer treatment using FAF1 protein-loaded exosomes are disclosed. FAF1 protein-loaded exosomes are isolated from HEK 293 cells in which FAF1 having a known tumor-suppressive function is overexpressed and administered the FAF1 protein-loaded exosomes to various tumor models in which pancreatic cancer cells (MIA PaCa-2), lung cancer cells (A549), colon cancer cells (HCT 116), liver cancer cells (Hep3B), breast cancer cells (MDA-MB-231), kidney cancer cells (Caki-1) and cervical cancer cell (HeLa cell) are transplanted into nude mice through intratumoral injection. The administration exhibited tumor growth inhibitory effects remarkably greater than those of a control group not treated with FAF1.
Absstract of: WO2024130106A1
A transcutaneous composition for treating an oxidative skin disorder of a mammal in need is disclosed containing an effective oxidative skin disorder treating amount of covalently-substituted oxidi zed activated charcoal (OACs) nanoparticles dissolved or dispersed in an aqueous composition containing a thickening agent providing a viscosity of about 1000 to about 20,000 cps, and about 5 to about 20 wt % of a skin permeation enhancer. A substituent of the substituted OAC comprises an average of about 2 to about 5 polyethylene glycol ( PEG) chains covalently linked to each OAC, or an average of about 2 to about 5 metal ion chelating groups covalently linked to each OAC, or an average of about 2 to about 5 PEG chains and an average of about 2 to about 5 metal ion chelating groups linked to each OAC. A method of treating an oxidative skin disorder of a mammal is also disclosed.
Absstract of: US2025302899A1
The present disclosure provides for an oncolytic virus comprising an exogenous nucleic acid encoding for a polypeptide that acts as a CD47-SIRP-alpha immune checkpoint inhibitor. Oncolytic viruses optionally comprise a mutation or deletion of the gene expressing IFN-gamma. Compositions described herein are further described for use in the treatment of cancer.
Absstract of: US2025381141A1
Formulation of nanoparticles of calcium phosphate, preferably hydroxyapatite, said nanoparticles being modified with lecithin, preferably phosphatidylcholine, said formulation having an enhanced cellular uptake and being a carrier for bisphosphonate, characterised in that bisphosphonate is selected from the group of bisphosphonate drugs approved for medical use, the group comprising alendronate and zoledronate, bisphosphonate is encapsulated in calcium phosphate nanoparticles in an amount up to 40% by mass, and the nanoparticles are less than 200 mn in size. Method of obtaining said formulation, comprising the steps: a. dissolving Ca(N03)2. 4H2O in a lecithin solution, b. dissolving (NH4)2HP04 in a bisphosphonate solution, c. adjusting the pH of the solution resulting from step a. and of the solution resulting from step b. to the value of 10, d. mixing the solutions from step c. in a reactor to obtain a suspension, e. centrifuging the suspension from step d. to obtain precipitate, f. purifying the precipitate from step e. by rinsing it four times with ultrapure water and centrifuging, g. drying the precipitate from step f. at 50° C. for 12-24 h, h. grinding the precipitate from step g. in a ball mill for 10 minutes at a speed of 150 rpm, wherein step d. is carried out in a continuous or batch reactor.
Absstract of: WO2025259188A1
There is provided a compound comprising a structure represented by general formula (1) or an ionized form thereof for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent wherein R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; R1, R2, R10, and R11 are each independently optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, or a single bond; R4, R5, R6, R7, R8, and R9 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; A1 and A2 are each independently a hydrophobic group or contains at least one of the groups defined above for R4 to R9, with the proviso that both A1 and A2 are not H at the same time; B1, B2, B3, and B4 are each independently -H, -ORa, -NRaRb, -SRa, - C(ORa)(Rb)(Rc), -C(SRa)(Rb)(Rc), or -C(NRaRb)(Rc)(Rd), where each of Ra, Rb, Rc, and Rd is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; w ≥ 0; x ≥ 1; and y ≥ 1.
Absstract of: WO2025259802A2
The present disclosure relates to compositions comprising a population of immunomodulatory lipid nanoparticles, as well as methods of using thereof to treat and/or prevent cancer (e.g., via local administration to the lymph nodes) and methods of using thereof to treat and/or prevent cancer metastasis in a subject.
Absstract of: WO2025259915A1
Methods are disclosed for inhibiting osteoclasts in a subject. These methods include selecting a subject in need of osteoclast inhibition and administering to the subject a composition comprising an effective amount of exogenous matrix bound nanovesicles (MBV) derived from a mammalian extracellular matrix, wherein the MBV do not express CD63 and CD81 or are CD63loCD81lo and wherein the MBV do not contain alkaline phosphatase. In specific, non-limiting examples, the subject can have periprosthetic osteolysis, osteoporosis or osteopenia.
Absstract of: WO2025259845A1
The present invention relates to compositions comprising sHDL nanoparticles and/or sHDL nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) therapeutic agents, and related methods of use for managing dental inflation and related conditions (e.g., apical periodontitis), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
Absstract of: WO2025258656A1
The present invention provides miRNA- or miRNA mimic-encapsulating lipid nanoparticles for use in the treatment of a pulmonary disease, the lipid nanoparticles each comprising an ionic lipid represented by formula (1), a phospholipid, a cholesterol, a PEG lipid, and an miRNA or miRNA mimic, wherein the amount of the ionic lipid represented by formula (1) is 20-60 mol%, the amount of the phospholipid is 7.5-50 mol%, the amount of the cholesterol is 10-40 mol%, and the amount of the PEG lipid is 0.5-15 mol% with respect to the total amount of the ionic lipid represented by formula (1), the phospholipid and the cholesterol. (In formula (1), the definitions for symbols are as described in the description.)
Absstract of: WO2025257777A1
Provided are improved immunogenic compositions, such as those comprising a nanodisc. In some aspects the nanodisc comprises a membrane scaffold protein (MSP), a phospholipid, and an immunogen, wherein the membrane scaffold protein and the immunogen are from different species. Provided is a method of inducing an improved immune response in a subject, the method comprising administering to the subject the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Provided is a system for inducing an immune response in a subject, comprising the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Provided is a system for active immunization to prevent a disease in a subject, the system comprising the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Preferably, MSP is not immunogenic to subject.
Absstract of: WO2025257768A1
Disclosed are imidazolium-based cationic lipid useful for non-viral delivery of nucleic acids. These imidazolium-based cationic lipid that can be formulated into lipid nanoparticle and encapsulated nucleic acid, such as small interfering RNA (siRNA) and messenger RNA (mRNA). The disclosure not only provides efficient siRNA delivery and excellent gene silencing, but also able to mediate mRNA translation to produce proteins of interest.
Absstract of: WO2025256283A1
Disclosed in the present invention are a CLDN18.2-targeting nanobody, and a preparation method therefor and the use thereof. Specifically disclosed are CLDN18.2-targeting nanobodies having amino acid sequences of SEQ ID NOs: 2, 4 and 20, respectively, and the uses thereof. The nanobody of the present invention has a high affinity and a good specificity, can bind to a CLDN18.2 antigen, has an anti-tumor activity, and cannot bind to other CLDN family members. The nanobody has few toxic and side effects, and thus can be prepared into a prophylactic and therapeutic drug for a Claudin 18.2 target-related disease, a diagnostic drug, a detection or in-vivo imaging product for a Claudin 18.2 protein, etc.
Absstract of: WO2025255866A1
Provided are nucleic acid molecules that encode a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) fusion protein comprising an antibody fragment that binds a neonatal fragment crystallizable (Fc) receptor (FcRn) and a GLP-1 analogue, GLP-1RA fusion proteins, lipid nanoparticles containing the nucleic acid, the GLP-1RA fusion protein, or an GLP-1 analogue, pharmaceutical compositions, and uses thereof, and methods of treating diseases and disorders such diseases and disorders amenable to treatment with a GLP-1RA.
Absstract of: WO2025255759A1
A biological complex and a micelle complex derived therefrom, and a preparation method therefor. In particular, the present invention relates to a micelle complex having a biologically active ingredient in the size range of 1 nm to 1000 nm, the biological complex being composed of a biologically active ingredient and a biopolymer, and the derivative micelle complex being composed of a biologically active ingredient, a biopolymer and a surfactant; the biologically active ingredient is selected from insulin, liraglutide, and semaglutide. The biological complex and the derived micelle complex are used for preparing a drug for regulating blood glucose or controlling body weight.
Absstract of: WO2025255669A1
The present disclosure includes hyperbranched polyether polyols, such as hyperbranched poly(3-(oxiran-2-ylmethoxy) propane-1,2-diol) (HPOD), methods for their preparation and uses thereof, for example, as a cryoprotectant, lyoprotectant or stabilizer.
Absstract of: US2025381299A1
The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg/mL. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.
Absstract of: US2025381132A1
The present invention relates to nucleic acid fragment-encapsulated polymer nanoparticles and a method of preparing the same. The polymer may be a mucoadhesive polymer and specifically chitosan, and the nucleic acid fragment may be polydeoxyribonucleotide (PDRN). The nucleic acid fragment-encapsulated polymer nanoparticles may be used as an eye drop. Since the nucleic acid fragment-encapsulated polymer nanoparticles is capable of adhering to the mucus in the eyes, nucleic acid fragments inside the nanoparticles can be slowly released into the ocular mucous membrane. In addition, since nucleic acid fragment-encapsulated polymer nanoparticles can exhibit high efficiency in the eyes even with a small dose of drug, patient convenience can be increased or costs can be reduced.
Absstract of: US2025382349A1
The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.
Absstract of: US2025382402A1
Provided herein are compositions including lipids and copolymers in the form of a nanodisc assembly. The subject copolymers include monomer units of styrene and monomer units selected from acrylic acid and an acrylic acid derivative. In certain cases, the copolymer is a copolymer of styrene and acrylic acid. Also provided herein, is an aqueous solution comprising the subject composition. Also provided herein, are methods for producing a nanodisc assembly, including incubation of a lipid and a subject copolymer. Further provided herein, are methods for solubilizing a membrane protein in an aqueous solution, wherein the method includes forming a nanodisc assembly of a lipid bilayer having one or more membrane proteins embedded therein, and a subject copolymer. Also provided are methods of solubilizing a hydrophobic constituent in an aqueous solution, including forming a nanodisc assembly of a lipid, a hydrophobic constituent, and a subject copolymer.
Absstract of: US2025382633A1
Disclosed herein is an adenoviral vector system utilizing DARPin adapters. The system is highly effective, safe and able to deliver DNA in a cell-specific manner. It is demonstrated that the system is unexpectedly versatile, and can be used in conjunction with protein scaffolds, bioactive peptides and small molecules. This makes the system useful for numerous purposes, including the use of the system for therapeutic and diagnostic purposes.
Absstract of: US2025382341A1
Compositions comprising at least one nanoparticle containing a nucleoside RNA molecule encoding FOXP3 and an optional second agent are described herein. In some cases, the RNA molecule is circular and contains one or more IRES. Methods for treating or preventing inflammation are also described herein.
Absstract of: US2025382376A1
A novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof are provided. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.
Absstract of: US2025381280A1
The present invention relates to a nanoplatform for targeting an inflammatory macrophage and a composition for preventing or treating inflammatory diseases using the same. The nanoplatform for targeting the inflammatory macrophage according to the present invention can selectively target the inflammatory macrophage with a conjugated glucosyl group as a transmitter. Furthermore, it can suppress inflammatory responses in damaged cells or tissues, restore mitochondrial function, and inhibit cell death, making it an effective composition for preventing or treating inflammatory diseases, particularly kidney diseases.
Nº publicación: US2025381300A1 18/12/2025
Applicant:
POSEIDA THERAPEUTICS INC [US]
Poseida Therapeutics, Inc
Absstract of: US2025381300A1
The present disclosure relates to compositions and methods for treating phenylketonuria (PKU). In particular, the present disclosure relates to AAV-piggyBac transposon polynucleotide vectors and LNP compositions comprising a nucleic acid encoding a transposase, and methods of using the compositions for treating PKU.
BOPI
Electronic site
